Clinical Trials

Numerous clinical trials, spanning Phase I through Phase IV, evaluate the efficacy, safety, and pharmacokinetics of ceftazidime alone or combined with beta-lactamase inhibitors like avibactam. Sponsored by academic medical centers, health systems, and pharmaceutical companies, these studies target carbapenem-resistant Enterobacteriaceae infections, melioidosis, hospital-acquired and ventilator-associated pneumonia, complicated intra-abdominal or urinary tract infections, and severe sepsis. The trials exhibit varying recruitment statuses, including completed, actively recruiting, not yet recruiting, and withdrawn.

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT07759453 NOT_YET_RECRUITING
Liver Transplant; Carbapenem-resistant Enterobacterales; CRE Colonization
IRCCS Azienda Ospedaliero-Universitaria di Bologna
 2026-10-01 PHASE3
NCT07004049 RECRUITING
Bloodstream Infection; Ventilator Associated Bacterial Pneumonia; Hospital Acquired Bacterial Pneumonia; Carbapenem Resistant Bacterial Infection; Multidrug Resistance
National University of Singapore
 2025-04-21 PHASE4
NCT06406114 RECRUITING
Drug Allergy; Cephalosporin Allergy; Drug Hypersensitivity; Antibiotic Allergy; Beta Lactam Adverse Reaction; Drug-Induced Anaphylaxis; Cephalosporin Reaction
Massachusetts General Hospital
 2025-05-05 PHASE2
NCT07327619 RECRUITING
Hospital-acquired Bacterial Pneumonia and Ventilator-associated Bacterial Pneumonia
Qilu Pharmaceutical Co., Ltd.
 2026-01-22 PHASE3
NCT07634198 NOT_YET_RECRUITING
Hospital-acquired Bacterial Pneumonia (HABP); Ventilator-associated Bacterial Pneumonia (VABP)
Nanjing Yoko Biomedical Co., Ltd.
 2026-06-04 PHASE3
NCT07431307 NOT_YET_RECRUITING
Ventilator Associated Bacterial Pneumonia (VABP); Hospital Acquired Bacterial Pneumonia (HABP); Blood Stream Infection; Meningitis, Bacterial; Ventriculitis, Infectious
BioVersys AG
 2026-07 PHASE2
NCT06939829 NOT_YET_RECRUITING
Patients With Critically Ill Infections
Southeast University, China
 2025-05-01 PHASE4
NCT07478484 RECRUITING
Ceftazidime-avibactam; Aztreonam; Gram-negative Bacterial Infection; Metallo-β-lactamase-producing; Carbapenem-resistant
Jing Zhou
 2026-03-31 PHASE4
NCT06633718 NOT_YET_RECRUITING
Intra-abdominal Infections
Qilu Pharmaceutical Co., Ltd.
 2024-10-31 PHASE3
NCT06811727 NOT_YET_RECRUITING
Severe Infection
Ivan Šitum, MD
 2025-05-01 PHASE4
NCT06818565 NOT_YET_RECRUITING
Acute-On-Chronic Liver Failure
Institute of Liver and Biliary Sciences, India
 2025-02-10
NCT07063095 RECRUITING
Gram Negative Infections; Sepsis and Septic Shock
Angela HUTTNER
 2025-08-25 PHASE3
NCT07085624 NOT_YET_RECRUITING
Infection in ICU; Sepsis; Septic Shock; Pseudomonas Aeruginosa Infection
Centre Hospitalier Universitaire de Saint Etienne
 2026-01
NCT05979545 RECRUITING
Blood Stream Infections; Ventilator Associated Pneumonia; Healthcare Associated Infection; Carbapenem-Resistant Enterobacteriaceae Infection; Hospital-acquired Pneumonia
National University of Singapore
 2023-12-12 PHASE4
NCT04948463 COMPLETED
Febrile Neutropenia
Murdoch Childrens Research Institute
 2021-11-15 PHASE4
NCT07016165 RECRUITING
Neutropenic Fever; Acute Lymphoblastic Leukemia; Acute Myeloblastic Leukemia; Non Hodgkin Lymphoma
Gadjah Mada University
 2025-06-01 PHASE4
NCT06528028 UNKNOWN
Anti-Infective Agent
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
 2024-07-01 PHASE4
NCT05977868 TERMINATED
Endovascular Infection; Bone and Joint Infection; Skin and Soft Tissue Infection; Pulmonary Infection; Gastrointestinal Infection; Genitourinary Infection
West Virginia University
 2023-08-04 PHASE4
NCT05850871 UNKNOWN
Carbapenem-Resistant Enterobacteriaceae Infection
Qianfoshan Hospital
 2023-01-06
NCT06210542 Not yet recruiting
ECMO|Carbapenem-Resistant Enterobacteriaceae Infection
Sichuan Provincial People''s Hospital
 2024-01 --
NCT06089668 Recruiting
Melioidosis
AN2 Therapeutics Inc|Mahidol Oxford Tropical Medicine Research Unit
 2023-11-01 --
NCT05105035 COMPLETED
Melioidosis
Arrevus Inc.
 2022-06-14 PHASE2
NCT04882085 COMPLETED
Urinary Tract Infection; Acute Pyelonephritis; Hospital Acquired Pneumonia; Ventilator-associated Pneumonia; Bacteremia; Intra-abdominal Infection
Pfizer
 2021-08-26 PHASE4
NCT04774094 COMPLETED
Hospital-Acquired Pneumonia
Pfizer
 2021-05-21 PHASE4
NCT05258851 TERMINATED
Carbapenem-Resistant Enterobacteriaceae Infection
King Faisal Specialist Hospital & Research Center
 2022-06-01 PHASE3
NCT04785924 WITHDRAWN
Carbapenem-Resistant Enterobacteriaceae Infection; KPC; Gram-Negative Bacterial Infections; Antibiotic Resistant Infection
Wake Forest University Health Sciences
 2021-06-07 PHASE4
NCT04126031 TERMINATED
Gram-negative Bacterial Infection
Pfizer
 2020-01-14 PHASE2
NCT03790176 UNKNOWN
Peritonitis; Pneumonia
Markus Zeitlinger
 2018-10-01 PHASE1
NCT05487586 Recruiting
Hospital Acquired Pneumonia|Ventilator Acquired Pneumonia|Complicated Intra Abdominal Infections
Pfizer
 2022-10-20 --
NCT04927312 COMPLETED
Complicated Intra-abdominal Infection
Pfizer
 2021-10-01 PHASE3
NCT01601093 SUSPENDED
Respiratory Tract Infections; Urinary Tract Infections
Xiangbei Welman Pharmaceutical Co., Ltd
 2011-11 PHASE2
NCT05413343 Recruiting
Severe Sepsis
First Affiliated Hospital of Zhejiang University
 2022-01-01 --
NCT04927312 Completed
Complicated Intra-abdominal Infection
Pfizer
 2021-10-01 Phase 3
NCT04040621 TERMINATED
Hospitalized Children With Suspected or Confirmed Nosocomial Pneumonia
Pfizer
 2020-06-15 PHASE1
NCT03754387 UNKNOWN
Chronic Appendicitis
Zunyi Medical College
 2019-01-01
NCT03978091 COMPLETED
Bacterial Infection
National Institute of Allergy and Infectious Diseases (NIAID)
 2019-07-09 PHASE1; PHASE2
NCT03634904 UNKNOWN
Bacterial Infections; Ceftazidime; Renal Failure Chronic Requiring Hemodialysis
Centre Hospitalier Universitaire de Charleroi
 2018-09-15
NCT04187755 COMPLETED
Neutropenia, Febrile; Leukemia; Pediatric Cancer; Antibiotic Reaction
Indonesia University
 2019-03-01 PHASE4
NCT02593201 COMPLETED
Peritoneal Dialysis
Chinese University of Hong Kong
 2016-02-26 PHASE4
NCT03404739 UNKNOWN
Esophageal Achalasia
Shanghai Zhongshan Hospital
 2017-10-01 PHASE2; PHASE3
NCT03376529 COMPLETED
Healthy Volunteers
Spero Therapeutics
 2017-11-10 PHASE1
NCT02822950 COMPLETED
Pharmacokinetics of Avycaz in ICU Patients
Michigan State University
 2017-01 PHASE1
NCT02497781 COMPLETED
Complicated Urinary Tract Infections
Pfizer
 2015-09-24 PHASE2
NCT02840136 TERMINATED
Cystic Fibrosis
University Ghent
 2016-02
NCT01667094 UNKNOWN
Cystic Fibrosis
The Alfred
 2012-09 PHASE4
NCT02526004 COMPLETED
Cystic Fibrosis
University College Cork
 2013-10-01
NCT02475733 COMPLETED
Complicated Intra-abdominal Infections
Pfizer
 2015-08-01 PHASE2
NCT01828892 UNKNOWN
Low-output External Gastrointestinal Fistula
Jinling Hospital, China
 2014-03
NCT02872038 COMPLETED
Peritoneal Dialysis Associated Peritonitis
Chulalongkorn University
 2015-08 PHASE4
NCT02504827 COMPLETED
Cystic Fibrosis
University of Southern California
 2015-09 PHASE4
NCT02732327 TERMINATED
Neoplasms; Febrile Neutropenia
Forest Laboratories
 2016-05-17 PHASE2
NCT02787057 COMPLETED
Peritoneal Dialysis Associated Peritonitis
Peking University First Hospital
 2012-11
NCT01808092 COMPLETED
Nosocomial Pneumonia (NP); Ventilator-associated Pneumonia (VAP)
Pfizer
 2013-04 PHASE3
NCT01507532 WITHDRAWN
Renal Failure
Midwestern University
 2012-01 PHASE4
NCT01726023 COMPLETED
Complicated Intra-abdominal Infection
Pfizer
 2013-01 PHASE3
NCT01893346 COMPLETED
Systemic Infections
Pfizer
 2013-07 PHASE1
NCT01344512 COMPLETED
Pediatrics; Ceftazidime; Ciprofloxacin; Voriconazole
University Hospital, Bordeaux
 2011-06
NCT01784445 COMPLETED
Pancreatitis
University Hospital Rijeka
 2013-06 PHASE4
NCT01644643 COMPLETED
Complicated Urinary Tract Infection; Complicated Intra-abdominal Infection
Pfizer
 2013-01 PHASE3
NCT01595438 COMPLETED
Complicated Urinary Tract Infection (cUTI) Including Acute Pyelonephritis
Pfizer
 2012-10 PHASE3
NCT01599806 COMPLETED
Complicated Urinary Tract Infection (cUTI) Including Acute Pyelonephritis
Pfizer
 2012-10 PHASE3
NCT01499290 COMPLETED
Complicated Intra-Abdominal Infection
Pfizer
 2012-03 PHASE3
NCT01455246 TERMINATED
Cirrhosis; Ascites; Nosocomial Spontaneous Bacterial Peritonitis
University of Padova
 2010-10 PHASE2; PHASE3
NCT01785641 COMPLETED
Peritonitis
Chulalongkorn University
 2012-12
NCT01920399 COMPLETED
Healthy Volunteers
Pfizer
 2013-10 PHASE1
NCT01430910 COMPLETED
Healthy
Pfizer
 2011-09 PHASE1
NCT01395420 COMPLETED
Healthy
Pfizer
 2011-08 PHASE1
NCT01534247 COMPLETED
Healthy
Pfizer
 2012-02 PHASE1
NCT01290900 COMPLETED
Healthy Male Volunteers
Pfizer
 2011-02 PHASE1
NCT01291602 COMPLETED
Healthy Male and Female Japanese Volunteers
Pfizer
 2011-02 PHASE1
NCT01044719 UNKNOWN
Cystic Fibrosis
Imperial College London
 2010-01 PHASE4
NCT00579956 UNKNOWN
Melioidosis
University of Oxford
 2007-12
NCT00690378 COMPLETED
Complicated Urinary Tract Infection
Pfizer
 2008-11 PHASE2
NCT00921024 COMPLETED
Complicated Urinary Tract Infection
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
 2009-06-30 PHASE2
NCT00752219 COMPLETED
Complicated Intra-abdominal Infections
Pfizer
 2009-03-31 PHASE2
NCT00786305 COMPLETED
Pneumonia
Groupe Hospitalier Pitie-Salpetriere
 2004-10 PHASE2
NCT00823238 COMPLETED
Cystic Fibrosis
University of North Carolina, Chapel Hill
 2004-07 PHASE1
NCT02837835 COMPLETED
Pneumonia
CHU de Reims
 2005-03 PHASE3
NCT00210964 COMPLETED
Pneumonia
Basilea Pharmaceutica
 2005-04 PHASE3
NCT00229008 COMPLETED
Pneumonia
Basilea Pharmaceutica
 2005-11 PHASE3
NCT00210899 COMPLETED
Skin Diseases, Infectious; Skin Diseases, Bacterial; Staphylococcal Skin Infections
Basilea Pharmaceutica
 2005-09 PHASE3
NCT00333385 TERMINATED
Cystic Fibrosis; Pseudomonas Aeruginosa; Pulmonary Exacerbation
Association Nationale pour les Traitements A Domicile, les Innovations et la Recherche
 2001-10 PHASE4
NCT00173901 UNKNOWN
Infection
National Taiwan University Hospital
 2001-03 PHASE4
NCT00752882 UNKNOWN
Pseudomonas Aeruginosa Meningitis
University Hospital, Clermont-Ferrand
 PHASE2
NCT00153634 COMPLETED
Cystic Fibrosis; Chronic Bronchitis
Seattle Children's Hospital
 2004-03
NCT00360607 COMPLETED
Infection
Pfizer
 2004-07 PHASE4

(data from https://clinicaltrials.gov, updated on 2026-08-12)

Check the Ceftazidime product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.

Compliance for Clinical Use

Mechanism and Biochemical Profile

Ceftazidime is a third-generation cephalosporin antibiotic that selectively binds to and inactivates essential penicillin-binding proteins involved in bacterial cell wall synthesis, thereby inhibiting peptidoglycan cross-linking and triggering osmotic cell lysis. This bactericidal action provides the biological rationale for its clinical use and investigation in treating serious bacterial conditions, including hospital-acquired pneumonia, complicated intra-abdominal infections, complicated urinary tract infections, and carbapenem-resistant Enterobacteriaceae infections.

Appendix RUO and cGMP Quality Standards

Quality Dimension RUO (Research Use Only) cGMP (Current Good Manufacturing Practice)
Clinical Applicability Prohibited in human clinical trials or medical diagnostics. Mandatory for human clinical trials (Phase I–III) and therapies.
Regulatory Status Non-regulated grade; exempt from drug manufacturing laws. Legally enforced by health authorities (e.g., FDA, EMA, NMPA).
Facility Environment Unclassified analytical or research laboratories. Validated Cleanrooms (ISO Class 5–8) with continuous monitoring.
Quality Control Basic purity and activity testing. Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma).
Process Validation Basic equipment calibration; no process validation required. Full qualification (IQ/OQ/PQ) and complete batch records.
Quality Assurance Vendor self-declared without required formal QMS. Mandatory QA/QC unit, Change Control, CAPA, and vendor audits.
Regulatory Impact High risk of IND rejection if used as a critical raw material. Required for IND/NDA filings, supported by Drug Master Files (DMF).

Footnotes

Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).

Jump to

Note: Technical data last updated: Sep 1, 2026.